Bill & Melinda Gates Medical Research Institute
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Private
- Established
- 2017-01-01
- Employees
- 101
- Market Cap
- -
- Website
- https://www.gatesmri.org
A Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, and Behavior in the Body of TBD11
- First Posted Date
- 2024-11-27
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Bill & Melinda Gates Medical Research Institute
- Target Recruit Count
- 108
- Registration Number
- NCT06707142
- Locations
- πΊπΈ
Celerion, Lincoln, Nebraska, United States
Study To Evaluate Safety, Tolerability, and Pharmacokinetics of MAM01 in African Population
Phase 1
Recruiting
- Conditions
- Healthy Volunteers
- Interventions
- Drug: MAM01 150 mg SCDrug: MAM01 150 mg IMDrug: MAM01 100 mg SCDrug: MAM01 300 mg SCDrug: MAM01 300 mg IMDrug: MAM01 2000 mg IVDrug: MAM01 190 mg SCDrug: MAM01 225 mg SCDrug: MAM01 150 mg IVDrug: Placebo SCDrug: Placebo IMDrug: Placebo IV
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Bill & Melinda Gates Medical Research Institute
- Target Recruit Count
- 139
- Registration Number
- NCT06408857
- Locations
- πΊπ¬
JCRC-Joint Clinical Research Centre, Kampala, Uganda
πΊπ¬IDRC-Infectious Disease Research Collaboration, IDRC Tororo Hospital Station Road, Tororo, Uganda
Study to Assess Efficacy and Safety of M72/AS01E-4 Mycobacterium Tuberculosis (Mtb) Vaccine in Adolescents and Adults
Phase 3
Active, not recruiting
- Conditions
- Tuberculosis
- Interventions
- Biological: PlaceboBiological: M72/AS01E-4 Mycobacterium tuberculosis investigational vaccine
- First Posted Date
- 2023-10-02
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Bill & Melinda Gates Medical Research Institute
- Target Recruit Count
- 20081
- Registration Number
- NCT06062238
- Locations
- π°πͺ
1209-Gates MRI Investigational Site, Nairobi, Kenya
π°πͺ1201-Gates MRI Investigational Site, Nairobi, Kenya
π²πΌ2402-Gates MRI Investigational Site, Chichiri, Malawi
Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis
Phase 2
Terminated
- Conditions
- Pulmonary Tuberculosis
- Interventions
- Drug: Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS)Drug: Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS)Drug: Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE)
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Bill & Melinda Gates Medical Research Institute
- Target Recruit Count
- 93
- Registration Number
- NCT05971602
- Locations
- π΅π
Lung Center of the Philippines, Quezon City, Philippines
πΏπ¦The Aurum Institute (Tembisa CRS), Johannesburg, South Africa
πΏπ¦Perinatal HIV Research Unit (PHRU), Klerksdorp, South Africa
Impact of Bi-26 Supplementation on Weight Gain in Underweight Infants
Phase 3
Terminated
- Conditions
- UnderweightPaediatrics
- Interventions
- Dietary Supplement: PlaceboDietary Supplement: B. infantis Bi-26
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Bill & Melinda Gates Medical Research Institute
- Target Recruit Count
- 40
- Registration Number
- NCT05952076
- Locations
- π΅π°
Medical Facility A, Islamabad, Islamabad Capital Territory, Pakistan
π΅π°Medical Facility B, Islamabad, Islamabad Capital Territory, Pakistan
π΅π°Medical Facility C, Islamabad, Islamabad Capital Territory, Pakistan
Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults
Phase 1
Completed
- Conditions
- Malaria
- Interventions
- Biological: MAM01 900 mgBiological: MAM01 1.5 mg/kgBiological: MAM01 5 mg/kgBiological: MAM01 450 mgBiological: MAM01 600 mgOther: ControlBiological: PlaceboBiological: MAM01 10 mg/kgBiological: MAM01 40 mg/kg
- First Posted Date
- 2023-06-06
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Bill & Melinda Gates Medical Research Institute
- Target Recruit Count
- 61
- Registration Number
- NCT05891236
- Locations
- πΊπΈ
Center for Vaccine Development and Global Health, 685 W. Baltimore Street, Baltimore, Maryland, United States
Safety, Tolerability, Pharmacokinetics (PK), and Food Effect of MK-7762 in Healthy Adults
Phase 1
Completed
- Conditions
- Tuberculosis
- Interventions
- Drug: MK-7762 (TBD09)Other: Placebo
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Bill & Melinda Gates Medical Research Institute
- Target Recruit Count
- 119
- Registration Number
- NCT05824091
- Locations
- πΊπΈ
Investigational Site, Lincoln, Nebraska, United States
Epidemiologic Study to Assess the IGRA Positivity in Populations With a High TB Burden
Completed
- Conditions
- Tuberculosis, Pulmonary
- First Posted Date
- 2022-01-13
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Bill & Melinda Gates Medical Research Institute
- Target Recruit Count
- 7203
- Registration Number
- NCT05190146
- Locations
- πΏπ²
Investigational Site, Ndola, Zambia
Safety, Tolerability, and Pharmacokinetics of RSV Monoclonal Antibody RSM01 in Healthy Adults
- First Posted Date
- 2021-11-12
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Bill & Melinda Gates Medical Research Institute
- Target Recruit Count
- 56
- Registration Number
- NCT05118386
- Locations
- πΊπΈ
PPD Phase I Clinic - Orlando, Orlando, Florida, United States
Proof of Concept Trial of Adjuvant Activity of SWE, a Squalene-based -Oil-in-water Emulsion
Phase 1
Withdrawn
- Conditions
- Influenza
- Interventions
- Biological: SWE adjuvant mixed with unadjuvanted seasonal influenza vaccine shortly before dosing (SWE + QIV)Biological: Unadjuvanted seasonal influenza vaccineBiological: MF59 adjuvanted seasonal influenza vaccine
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Bill & Melinda Gates Medical Research Institute
- Registration Number
- NCT05035680
Β© Copyright 2025. All Rights Reserved by MedPath